SpringWorks Therapeutics (NASDAQ:SWTX) Receives Neutral Rating from Guggenheim
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at Guggenheim in a research note issued to investors on Monday,Benzinga reports. They presently have a $47.00 price target on the stock. Guggenheim’s price target points to a potential upside of 1.69% from the company’s current price. A […]
SpringWorks Therapeutics (NASDAQ:SWTX – Get Free Report)‘s stock had its “neutral” rating restated by equities research analysts at Guggenheim in a research note issued to investors on Monday,Benzinga reports. They presently have a $47.00 price target on the stock. Guggenheim’s price target points to a potential upside of 1.69% from the company’s current price. A […]
